Sysmex Corporation TSE:6869
Sysmex : Financial Data( PDF format / 741KB )
Source: MarketScreener
FINANCIAL DATA (IFRS)
Full Year
Fiscal Year Ended March 31, 2026
[2026年3月期 通期]
April 1, 2025 - March 31, 2026
⽬次 CONTENTS
連結決算概要／Financial Summary (Consolidated) 1
連結財政状態計算書／Consolidated statement of financial position 3
連結損益計算書／Consolidated statement of income 5
連結キャッシュ・フ□ー計算書／Consolidated statement of cash flows 6
地域別・事業別・品⽬別売上⾼／Net Sales by Destination,Business and Product type 8
地域別・事業別売上⾼／Net Sales by Destination and Business 9
地域別・品⽬別売上⾼／Net Sales by Destination and Product type 12
統括会社別売上⾼および営業利益の状況／Net Sales and Operating Income (Loss) by Geographical Region 13
関連データ／Associated Data 14
会社概要／Corporate Data 15
補⾜事項 Notes
2026年4⽉1⽇にシスメックスBioMajesty株式会社を⼦会社化しました。
In April 1, 2026, Sysmex BioMajesty Co., Ltd. became a subsidiary.
2026年3⽉期第1四半期にシスメックス グリース アイケーイーをギリシャに設⽴しました。
In the 1st quarter of the fiscal year ended March 31, 2026, Sysmex established Sysmex Greece I.K.E., in Greece.
2025年3⽉期第4四半期にシスメックス イーストアフリカをケニアに設⽴しました。
In the 4th quarter of the fiscal year ended March 31st, 2025, Sysmex established Sysmex East Africa Ltd., in Kenya. 2025年3⽉期第1四半期より、報告セグメントを「所在地別」から「統括会社 別」へ変更しました。
From the first quarter of the fiscal year ending March 31, 2025, we have revised our reportable segments to be by managing company rather than by geographic segment.
2024年3⽉期第3四半期に株式会社メガカリオンを⼦会社化しました。
In the third quarter of the fiscal year ended March 31, 2024, Megakaryon Corporation became a subsidiary.
2023年3⽉期第2四半期にシスメックスピ□ート株式会社を⼦会社化しました。
In the second quarter of the fiscal year ended March 31, 2023, Sysmex Pilot Co., Ltd. became a subsidiary.
注意事項 Cautionary Notes
本資料のうち、業績⾒通し等に記載されている各数値は、現在⼊⼿可能な情報による判断および仮定に基づき算出しており、判断や仮定に内在する不確定性および今後の事業運営や内外の状況変化により、実際の業績等が⾒通しの数値と⼤きく異なる可能性があります。
This material contains forward-looking statements about Sysmex Corporation and its group companies (the Sysmex Group). These forward-looking statements are based on current judgments and assumptions of the Sysmex Group in light of the information currently available to it, and involve known and unknown risks, uncertainties and other factors, including but not limited to: global economic conditions, competitive situations and changes in exchange rates. Such risks, uncertainties and other factors may cause our actual results, performance, achievements or financial position to be materially different from any future results, performance, achievements or financial position expressed or implied by these forward-looking statements.
連結決算概要 通期累計 Financial Summary (Consolidated)[Full Year]
（百万円）（JPY million）
項⽬ Item | 決算期 Fiscal Term | 2022.3 FY | 2023.3 FY | 2024.3 FY | 2025.3 FY | 2026.3 FY | 2027.3 通期予想 Forecast | |
売上⾼ | Net sales | 363,780 | 410,502 | 461,510 | 508,643 | 500,006 | 535,000 | |
売上原価 | Cost of sales | 173,195 | 194,419 | 219,013 | 236,665 | 244,324 | 267,000 | |
売上総利益 | Gross profit | 190,585 | 216,082 | 242,497 | 271,977 | 255,681 | 268,000 | |
販売 及び⼀般管理 | Selling, general and administrative expenses | 94,235 | 112,371 | 133,798 | 150,848 | 164,351 | 181,000 | |
研究開発 | Research and development expenses | 26,784 | 31,060 | 31,402 | 31,455 | 29,162 | 30,000 | |
その他の営業損益 | Other operating income (expenses) | △2,148 | 1,030 | 1,086 | △2,089 | △10,336 | 1,000 | |
営業利益 | Operating profit | 67,416 | 73,679 | 78,382 | 87,583 | 51,831 | 58,000 | |
当期利益 | Profit | 44,071 | 45,725 | 49,774 | 53,576 | 35,374 | 36,000 | |
親会社の所有者に帰属す る当期利益 | Profit attributable to owners of the parent | 44,093 | 45,784 | 49,639 | 53,669 | 35,457 | 36,000 | |
希薄化後1株当たり当期利 益（円） | Diluted earnings per share(￥) | 70.16 | 72.91 | 79.24 | 86.05 | 56.89 | 57.93 | |
親会社所有者帰属持分当 期利益率 | Return on equity［ROE］ | 13.5 | 12.4 | 12.1 | 12.0 | 7.3 | 7.3 | |
売上総利益率 | Gross profit per net sales | 52.4 | 52.6 | 52.5 | 53.5 | 51.1 | 50.1 | |
売上⾼営業利益率 | Operating profit to net sales | 18.5 | 17.9 | 17.0 | 17.2 | 10.4 | 10.8 | |
売上⾼当期利益率 | Profit attributable to owners of the parent to net sales | 12.1 | 11.2 | 10.8 | 10.6 | 7.1 | 6.7 | |
売上⾼研究開発 率 | R&D expenditure per net sales | 7.4 | 7.6 | 6.8 | 6.2 | 5.8 | 5.6 |
項⽬ Item | 決算期 Fiscal Term | 2022.3 F.Y. | 2023.3 F.Y. | 2024.3 F.Y. | 2025.3 F.Y. | 2026.3 FY |
資本⾦ | Capital stock | 14,112 | 14,282 | 14,729 | 14,887 | 14,898 |
⾃⼰株式控除後期末株式 数（千株） | Number of outstanding stock excluding treasury stock (thousand shares) | 627,630.3 | 627,739.5 | 623,498.7 | 623,599.8 | 621,484.7 |
資本合計 | Total equity | 349,053 | 388,356 | 432,897 | 464,534 | 505,676 |
資産合計 | Total assets | 483,707 | 531,074 | 618,920 | 665,268 | 707,532 |
親会社所有者帰属持分⽐ 率 | Equity attributable to owners of the parent to total assets | 72.0 | 73.0 | 69.8 | 69.7 | 71.4 |
１株当たり親会社所有者 帰属持分(円） | Equity attributable to owners of the parent per share（￥） | 554.94 | 617.56 | 692.94 | 743.71 | 812.57 |
決算期 Fiscal Term
項⽬ Item
営業活動によるキ ャッシュ・フ□ー投資活動によるキャッシュ・フ□ー財務活動によるキャッシュ・フ□ー
現⾦及び現⾦同等 物の期末残⾼
2022.3 FY
2023.3 FY
2024.3 FY
2025.3 FY
2026.3 FY
Net cash provided by (used in) operating activities
Net cash provided by (used in) investment activities
Net cash provided by (used in) financing activities Cash and cash equivalents at the end of the term
58,739
△ 35,052
△ 20,542
73,752
68,835
△ 51,751
△ 24,234
69,460
63,905
△ 54,970
△ 9,013
75,507
88,246
△ 52,488
△ 24,322
89,570
73,848
△ 51,472
△ 37,659
84,117
項⽬ Item
設備投資 ※
減価償却 及 び償却
2022.3 FY
2023.3 FY
2024.3 FY
2025.3 FY
2026.3 FY
Capital expenditure ※
Depreciation and amortization
33,271
27,431
42,034
31,807
50,868
35,888
48,673
39,033
50,328
46,437
設備投資の状況 Capital Expenditure
※有形、無形含む
※Includes both tangible and intangible assets
●通期予想は、2026年5⽉に公表したものです。
Business forecast was revised in May 2026.
2027.3 通期予想
Forecast
48,000
47,000
1
決算 期 | Fiscal Term | 2022.3 F.Y. | 2023.3 F.Y. | 2024.3 F.Y. | 2025.3 F.Y. | 2026.3 F.Y. | ||
USドル | USD | （円） | (JPY) | 112.4 | 135.5 | 144.6 | 152.6 | 150.8 |
ユー□ | EUR | （円） | (JPY) | 130.6 | 141.0 | 156.8 | 163.8 | 174.8 |
元 | CNY | （円） | (JPY) | 17.5 | 19.8 | 20.1 | 21.1 | 21.2 |
換算レート（通期実績） Average Exchange Rate (Annual)
2027.3 通期予想
Forecast
155.0
180.0
22.0
●通期予想は、2026年5⽉に公表したものです。
●Business forecast was revised in May 2026.
資産 Assets （百万円）（構成⽐︓%）（JPY million）(Ratio︓%)
項⽬ Item | 2022.3 F.Y. | 2023.3 F.Y. | 2024.3 F.Y. | 2025.3 F.Y. | 2026.3 FY | 増減 (Variance) | ||||||
Ratio | Ratio | Ratio | Ratio | Ratio | ||||||||
流動資産 | Current assets | |||||||||||
現⾦及び現⾦同等物 | Cash and cash equivalents | 73,752 | 15.2 | 69,460 | 13.1 | 75,507 | 12.2 | 89,570 | 13.5 | 84,117 | 11.9 | △5,453 |
営業債権及びその他の 債権 | Trade and other receivables | 118,697 | 24.5 | 126,319 | 23.8 | 157,067 | 25.4 | 163,007 | 24.5 | 168,783 | 23.9 | 5,776 |
棚卸資産 | Inventories | 61,944 | 12.8 | 73,310 | 13.8 | 79,123 | 12.8 | 81,811 | 12.3 | 95,613 | 13.5 | 13,802 |
その他の短期⾦融資 産 | Other short-term financial assets | 1,498 | 0.3 | 875 | 0.2 | 1,310 | 0.2 | 654 | 0.1 | 775 | 0.1 | 121 |
未収法⼈所得税 | Income taxes receivable | 470 | 0.1 | 600 | 0.1 | 934 | 0.2 | 1,246 | 0.2 | 8,757 | 1.2 | 7,511 |
その他の流動資産 | Other current assets | 18,728 | 3.9 | 24,924 | 4.7 | 29,515 | 4.8 | 28,531 | 4.3 | 30,559 | 4.3 | 2,028 |
流動資産合計 | Total current assets | 275,092 | 56.9 | 295,491 | 55.6 | 343,459 | 55.5 | 364,821 | 54.8 | 388,606 | 54.9 | 23,785 |
⾮流動資産 | Non-current assets | |||||||||||
有形固定資産 | Property, plant and equipment | 98,525 | 20.4 | 102,106 | 19.2 | 116,693 | 18.9 | 130,211 | 19.6 | 150,396 | 21.3 | 20,185 |
のれん | Goodwill | 13,010 | 2.7 | 16,842 | 3.2 | 17,221 | 2.8 | 14,205 | 2.1 | 4,138 | 0.6 | △10,067 |
無形資産 | Intangible assets | 57,260 | 11.8 | 73,530 | 13.8 | 86,786 | 14.0 | 92,146 | 13.9 | 93,173 | 13.2 | 1,027 |
持分法で会計処理されている投資 | Investments accounted for using the equity method | 986 | 0.2 | 92 | 0.0 | 472 | 0.1 | 339 | 0.1 | 150 | 0.0 | △189 |
営業債権及びその他の 債権 | Trade and other receivables | 16,403 | 3.4 | 17,895 | 3.4 | 21,435 | 3.5 | 26,978 | 4.1 | 34,756 | 4.9 | 7,778 |
その他の⻑期⾦融資 産 | Other long-term financial assets | 9,157 | 1.9 | 9,777 | 1.8 | 14,034 | 2.3 | 12,034 | 1.8 | 14,025 | 2.0 | 1,991 |
退職給付に係る資産 | Asset for retirement benefits | 841 | 0.2 | 614 | 0.1 | 458 | 0.1 | 0 | 0.0 | 0 | 0.0 | - |
その他の⾮流動資産 | Other non-current assets | 3,910 | 0.8 | 3,842 | 0.7 | 4,339 | 0.7 | 6,880 | 1.0 | 6,643 | 0.9 | △237 |
繰延税⾦資産 | Deferred tax assets | 8,520 | 1.8 | 10,880 | 2.0 | 14,018 | 2.3 | 17,651 | 2.7 | 15,641 | 2.2 | △2,010 |
⾮流動資産合計 | Total non-current assets | 208,614 | 43.1 | 235,583 | 44.4 | 275,461 | 44.5 | 300,447 | 45.2 | 318,925 | 45.1 | 18,478 |
資産合計 | Total assets | 483,707 | 100.0 | 531,074 | 100.0 | 618,920 | 100.0 | 665,268 | 100.0 | 707,532 | 100.0 | 42,264 |
3
負債および資本 Liabilities and Equity （百万円）（構成⽐︓%）（JPY million）(Ratio︓%)
項⽬ Item | 決算期 Fiscal Term | 2022.3 F.Y. | 2023.3 F.Y. | 2024.3 F.Y. | 2025.3 F.Y. | 2026.3 FY | 増減 (Variance) | |||||
Ratio | Ratio | Ratio | Ratio | Ratio | ||||||||
負債 | Liabilities | |||||||||||
流動負債 | Current liabilities | |||||||||||
営業債務及びその他の 債務 | Trade and other payables | 32,111 | 6.6 | 31,678 | 6.0 | 33,602 | 5.4 | 31,865 | 4.8 | 34,116 | 4.8 | 2,251 |
リース負債 | Lease liabilities | 6,439 | 1.3 | 7,149 | 1.3 | 8,659 | 1.4 | 9,250 | 1.4 | 9,555 | 1.4 | 305 |
その他の短期⾦融負債 | Other short-term financial liabilities | 1,482 | 0.3 | 3,537 | 0.7 | 1,028 | 0.2 | 1,403 | 0.2 | 1,316 | 0.2 | △87 |
未払法⼈所得税 | Income taxes payable | 12,813 | 2.6 | 14,662 | 2.8 | 12,476 | 2.0 | 12,784 | 1.9 | 2,980 | 0.4 | △9,804 |
引当⾦ | Provisions | 1,234 | 0.3 | 1,123 | 0.2 | 1,159 | 0.2 | 1,164 | 0.2 | 1,342 | 0.2 | 178 |
契約負債 | Contract Liabilities | 12,852 | 2.7 | 14,469 | 2.7 | 16,591 | 2.7 | 18,098 | 2.7 | 20,770 | 2.9 | 2,672 |
未払 ⽤ | Accrued expenses | 17,498 | 3.6 | 18,772 | 3.5 | 21,643 | 3.5 | 22,355 | 3.4 | 22,610 | 3.2 | 255 |
未払賞与 | Accrued bonuses | 10,985 | 2.3 | 11,360 | 2.1 | 12,611 | 2.0 | 14,709 | 2.2 | 14,976 | 2.1 | 267 |
その他の流動負債 | Other current liabilities | 6,663 | 1.4 | 8,348 | 1.6 | 10,311 | 1.7 | 11,194 | 1.7 | 11,591 | 1.6 | 397 |
流動負債合計 | Total current liabilities | 102,082 | 21.1 | 111,102 | 20.9 | 118,084 | 19.1 | 122,826 | 18.5 | 119,259 | 16.9 | △3,567 |
⾮流動負債 | Non-current liabilities | |||||||||||
⻑期借⼊⾦ | Long-term loans payable | - | - | - | - | 28,600 | 4.6 | 32,359 | 4.9 | 31,646 | 4.5 | △713 |
リース負債 | Lease liabilities | 15,840 | 3.3 | 15,442 | 2.9 | 18,080 | 2.9 | 23,126 | 3.5 | 29,280 | 4.1 | 6,154 |
その他の⻑期⾦融負債 | Other long-term financial liabilities | 30 | 0.0 | 305 | 0.1 | 76 | 0.0 | 56 | 0.0 | 35 | 0.0 | △21 |
退職給付に係る負債 | Liability for retirement benefits | 1,183 | 0.2 | 1,959 | 0.4 | 2,239 | 0.4 | 2,127 | 0.3 | 2,238 | 0.3 | 111 |
引当⾦ | Provisions | 366 | 0.1 | 398 | 0.1 | 674 | 0.1 | 1,054 | 0.2 | 1,307 | 0.2 | 253 |
その他の⾮流動負債 | Other non-current liabilities | 8,537 | 1.8 | 7,059 | 1.3 | 10,350 | 1.7 | 11,608 | 1.7 | 12,198 | 1.7 | 590 |
繰延税⾦負債 | Deferred tax liabilities | 6,613 | 1.4 | 6,450 | 1.2 | 7,917 | 1.3 | 7,575 | 1.1 | 5,889 | 0.8 | △1,686 |
⾮流動負債合計 | Total non-current liabilities | 32,571 | 6.7 | 31,615 | 6.0 | 67,938 | 11.0 | 77,908 | 11.7 | 82,596 | 11.7 | 4,688 |
負債合計 | Total Liabilities | 134,654 | 27.8 | 142,718 | 26.9 | 186,023 | 30.1 | 200,734 | 30.2 | 201,856 | 28.5 | 1,122 |
資本 | Equity | |||||||||||
親会社の所有者に帰属 する持分 | Equity attributable to owners of the parent | |||||||||||
資本⾦ | Capital stock | 14,112 | 2.9 | 14,282 | 2.7 | 14,729 | 2.4 | 14,887 | 2.2 | 14,898 | 2.1 | 11 |
資本剰余⾦ | Capital surplus | 20,483 | 4.2 | 20,580 | 3.9 | 20,830 | 3.4 | 20,960 | 3.2 | 21,114 | 3.0 | 154 |
利益剰余⾦ | Retained earnings | 305,710 | 63.2 | 334,192 | 62.9 | 365,985 | 59.1 | 402,820 | 60.6 | 416,253 | 58.8 | 13,433 |
⾃⼰株式 | Treasury stock | △312 | 0.1 | △314 | 0.1 | △12,315 | 2.0 | △12,318 | 1.9 | △15,501 | 2.2 | △3,183 |
その他の資本の構成要 素 | Other components of equity | 8,309 | 1.7 | 18,925 | 3.6 | 42,814 | 6.9 | 37,425 | 5.6 | 68,236 | 9.6 | 30,811 |
親会社の所有者に帰属 する持分合計 | Total equity attributable to owners of the parent | 348,303 | 72.0 | 387,665 | 73.0 | 432,045 | 69.8 | 463,776 | 69.7 | 505,000 | 71.4 | 41,224 |
⾮⽀配持分 | Non-controlling interests | 750 | 0.2 | 690 | 0.1 | 851 | 0.1 | 758 | 0.1 | 675 | 0.1 | △83 |
資本合計 | Total equity | 349,053 | 72.2 | 388,356 | 73.1 | 432,897 | 69.9 | 464,534 | 69.8 | 505,676 | 71.5 | 41,142 |
負債及び資本合計 | Total liabilities and equity | 483,707 | 100.0 | 531,074 | 100.0 | 618,920 | 100.0 | 665,268 | 100.0 | 707,532 | 100.0 | 42,264 |
（百万円）（構成⽐︓%）（JPY million）(Ratio︓%)
決算期 Fiscal Term | 2022.3 FY | 2023.3 FY | 2024.3 FY | 2025.3 FY | 2026.3 FY | |||||||
項⽬ Item | Ratio | Ratio | Ratio | Ratio | Ratio | |||||||
売上⾼ | Net sales | 363,780 | 100.0 | 410,502 | 100.0 | 461,510 | 100.0 | 508,643 | 100.0 | 500,006 | 100.0 | |
売上原価 | Cost of sales | 173,195 | 47.6 | 194,419 | 47.4 | 219,013 | 47.5 | 236,665 | 46.5 | 244,324 | 48.9 | |
売上総利益 | Gross profit | 190,585 | 52.4 | 216,082 | 52.6 | 242,497 | 52.5 | 271,977 | 52.5 | 255,681 | 51.1 | |
販売 及び⼀般管理 | Selling, general and administrative expenses | 94,235 | 25.9 | 112,371 | 27.4 | 133,798 | 29.0 | 150,848 | 29.7 | 164,351 | 32.9 | |
研究開発 | Research and development expenses | 26,784 | 7.4 | 31,060 | 7.6 | 31,402 | 6.8 | 31,455 | 6.2 | 29,162 | 5.8 | |
減損損失 | Impairment loss | - | - | 2,368 | 1 | 2,210 | 0.5 | 3,211 | 0.6 | 11,557 | 2.3 | |
その他の営業収益 | Other operating income | 1,409 | 0.4 | 4,103 | 1.0 | 4,203 | 0.9 | 2,070 | 0.4 | 3,659 | 0.7 | |
その他の 営業 | ⽤ | Other operating expenses | 3,557 | 1.0 | 705 | 0.2 | 905 | 0.2 | 948 | 0.2 | 2,439 | 0.5 |
営業利益 | Operating profit | 67,416 | 18.5 | 73,679 | 17.9 | 78,382 | 17.0 | 87,583 | 17.2 | 51,831 | 10.4 | |
⾦融収益 | Financial income | 550 | 0.2 | 863 | 0.2 | 937 | 0.2 | 1,078 | 0.2 | 865 | 0.2 | |
⾦融 ⽤ | Financial expenses | 909 | 0.2 | 1,566 | 0.4 | 2,386 | 0.5 | 3,518 | 0.7 | 4,359 | 0.9 | |
持分法による投資損益 | Share of profit (loss) of associates accounted for using the equity method | △3,561 | 1.0 | △2,923 | 0.7 | △2,849 | 0.6 | △2,071 | 0.4 | △1,364 | 0.3 | |
為替差損益 | Foreign exchange gain (loss) | 850 | 0.2 | △1,339 | 0.3 | 516 | 0.1 | △3,850 | 0.8 | 2,078 | 0.4 | |
税引前当期利益 | Profit before tax | 64,346 | 17.7 | 68,713 | 16.7 | 74,600 | 16.2 | 79,221 | 15.6 | 49,051 | 9.8 | |
法⼈所得税 ⽤ | Income taxes expenses | 20,274 | 5.6 | 22,988 | 5.6 | 24,826 | 5.4 | 25,645 | 5.0 | 13,676 | 2.7 | |
当期利益 | Profit | 44,071 | 12.1 | 45,725 | 11.1 | 49,774 | 10.8 | 53,576 | 10.5 | 35,374 | 7.1 | |
当期利益の帰属 | Profit attributable to | ||||||||||
親会社の所有者 | Owners of the parent | 44,093 | 12.1 | 45,784 | 11.2 | 49,639 | 10.8 | 53,669 | 10.6 | 35,457 | 7.1 |
⾮⽀配持分 | Non-controlling interests | △21 | 0.0 | △59 | 0.0 | 135 | 0.0 | △93 | 0.0 | △82 | 0.0 |
当期利益 | Profit | 44,071 | 12.1 | 45,725 | 11.1 | 49,774 | 10.8 | 53,576 | 10.5 | 35,374 | 7.1 |
1株当たり当期利益 | Earnings per share | ||||||||||
基本的1株当たり当期 利益 | Basic | 70.29 | - | 72.94 | - | 79.27 | - | 86.07 | - | 56.89 | - |
希薄化後1株当たり当 期利益 | Diluted | 70.16 | - | 72.91 | - | 79.24 | - | 86.05 | - | 56.89 | - |
5
連結キャッシュ・フロー計算書 Consolidated statement of cash flows
決算期 Fiscal Term
（百万円）（JPY million）
項⽬ Item
営業活動によるキャッシュ・フロー Cash flows from operating activities
税引前四半期利益 Profit before tax
減価償却 及び償却 Depreciation and amortization
減損損失 Impairment loss
受取利息及び受取配当⾦ Interest and dividends income
⽀払利息 Interest expenses
持分法による投資損益 Share of profit (loss) of associates accounted for using the equity method
固定資産等除却損 Loss on retirement of non-current assets
営業債権の増減額 Decrease (increase) in trade receivable
前渡⾦の増減額 Decrease (increase) in advance payments
棚卸資産の増減額 Decrease (increase) in inventories
営業債務の増減額 Increase (decrease) in trade payable
未払⾦の増減額 Increase (decrease) in accounts payable-other
契約負債の増減額 Increase (decrease) in contract liabilities
未払 ⽤の増減額 Increase (decrease) in accrued expense
未払⼜は未収消 税等の増減額 Incrrease(Decrease) in consumption taxes receivable and payable
未払賞与の増減額 Increase (decrease) in accrued bonuses
その他 Other
⼩計 Subtotal
利息及び配当⾦の受取額 Interest and dividend received
利息の⽀払額 Interest paid
法⼈所得税の⽀払額 Income taxes paid
営業活動によるキャッシュ・フロー Net cash provided by (used in) operating activities
2022.3 FY
64,346
27,431
-
-
-3,561
2,245
△10,297
832
△12,495
△5,055 1,108
158
2,044
△2,417 1,984
402
73,850
298
△704
△14,705 58,739
2023.3 FY
68,713
31,807
2,368
△704 1,133
2,923
265
△2,980
△983
△10,558
△13
△713 1,450
747
766
125
△920 93,425
676
△985
△24,281 68,835
2024.3 FY
74,600
35,888
2,210
△863 1,571
2,849
381
△21,987
474
△1,676 1,274
118
201
1,483
1,157
749
△4,769 93,665
598
△1,383
△28,974 63,905
2025.3 FY
79,221
39,033
3,211
△899 1,949
2,071
383
△7,150
706
△6,320
162
△520 1,720
1,113
△1,374 2,118
1,743
117,168
654
△1,853
△27,723 88,246
2026.3 FY
49,051
46,437
11,557
△812 2,241
1,364
784
6,830
△713
△8,998
710
922
1,181
△1,528
△2,087
△201
△1,578 105,161
581
△2,173
△29,720 73,848
（百万円）（JPY million）
決算期 Fiscal Term
項⽬ Item
投資活動によるキャッシュ・フロー Cash flows from investing activities
2022.3 FY
2023.3 FY
2024.3 FY
2025.3 FY
2026.3 FY
有形固定資産の取得による⽀出 | Purchases of property, plant and equipment | △12,768 | △17,485 | △25,610 | △29,226 | △32,904 |
有形固定資産の売却による収⼊ | Proceeds from sales of property, plant and equipment | 545 | 337 | 527 | 702 | 1,616 |
無形資産の取得による⽀ 出 | Purchases of intangible assets | △19,266 | △25,020 | △24,581 | △20,733 | △18,065 |
⻑期前払 ⽤の増加を伴 う⽀出 | Payments resulting in an increase in long-term prepaid expenses | △1,896 | △646 | △841 | △1,001 | △1,064 |
資本性⾦融商品の取得による⽀出 | Purchases of investments in equity instruments | △320 | △5,189 | △4,026 | △3,821 | △262 |
資本性⾦融商品の売却による収⼊ | Proceeds from sales of investments in equity instruments | - | - | - | 1,853 | 525 |
負債性⾦融商品の取得による⽀出 | Purchases of investments in debt instruments | - | - | - | △399 | △1,129 |
⼦会社⼜はその他の事業 の取得による⽀出 | Acquisitions of subsidiaries or other businesses | - | △2,984 | △574 | - | - |
定期預⾦の預⼊による⽀ 出 | Payments into time deposits | △640 | △711 | △1,460 | △1,544 | △1,277 |
定期預⾦の払戻による収 ⼊ | Proceeds from withdrawals of time deposits | 755 | 811 | 1,260 | 1,777 | 1,079 |
その他 | Other | △1,459 | △863 | 337 | △95 | 9 |
投資活動によるキャッシュ・フロー | Net cash provided by (used in) investing activities | △35,052 | △51,751 | △54,970 | △52,488 | △51,472 |
財務活動によるキャッシュ・フロー | Cash flows from financing activities | |||||
⻑期借⼊れによる収⼊ | Proceeds from long-term loans payable | - | - | 29,000 | 4,700 | - |
⻑期借⼊⾦の返済による⽀ 出 | Repayment of long-term loans payable | - | - | - | △626 | △713 |
株式の発⾏による収⼊ | Proceeds from Issuance of Common Stock | 1,384 | 267 | 703 | 248 | 16 |
⾃⼰株式の取得による⽀出 | Purchases of treasury stock | - | - | △12,001 | △2 | △3,214 |
配当⾦の⽀払額 | Dividends paid | △15,258 | △16,528 | △17,579 | △18,081 | △22,441 |
リース負債の返済による⽀払 額 | Repayments of lease liabilities | △6,577 | △7,959 | △9,068 | △10,561 | △11,316 |
その他 | Other | △90 | △13 | △67 | 2 | 8 |
財務活動によるキャッシュ・フロー | Net cash provided by (used in) financing activities | △20,542 | △24,234 | △9,013 | △24,322 | △37,659 |
現⾦及び現⾦同等物に係る換 算差額 | Effects of exchange rate changes on cash and cash equivalents | 4,139 | 2,858 | 6,125 | 2,627 | 9,830 |
現⾦及び現⾦同等物の純増 減額 | Net increase (decrease) in cash and cash equivalents | 7,284 | △4,291 | 6,047 | 14,062 | △5,453 |
現⾦及び現⾦同等物の期⾸ 残⾼ | Cash and cash equivalents at the beginning of the term | 66,467 | 73,752 | 69,460 | 75,507 | 89,570 |
現⾦及び現⾦同等物の期末 残⾼ | Cash and cash equivalents at the end of the term | 73,752 | 69,460 | 75,507 | 89,570 | 84,117 |
7
地域別・事業別・品⽬別売上⾼ Net Sales by Destination, Business and Product type
地域別売上⾼ Net Sales by Destination （百万円）（構成⽐・対前年⽐︓%）（JPY million）(Ratio･Y O Y︓%)
決算期 Fiscal Term 地域 Destination | 2022.3 FY | 2023.3 FY | 2024.3 FY | 2025.3 FY | 2026.3 FY | 2027.3 通期予想 Forecast | |||||||||||
Ratio | Y O Y | Ratio | Y O Y | Ratio | Y O Y | Ratio | Y O Y | Ratio | Y O Y | Ratio | |||||||
国 内 Japan | 55,618 | 15.3 | 114.1 | 59,832 | 14.6 | 107.6 | 62,184 | 13.5 | 103.9 | 67,786 | 13.3 | 109.0 | 58,603 | 11.7 | 86.5 | 72,000 | 13.5 |
⽶州 Americas | 83,655 | 23.0 | 127.0 | 105,905 | 25.8 | 126.6 | 118,782 | 25.7 | 112.2 | 131,148 | 25.8 | 110.4 | 139,254 | 27.9 | 106.2 | 152,000 | 28.4 |
EMEA※1 EMEA | 94,352 | 72.0 | 121.3 | 105,200 | 71.1 | 111.5 | 125,349 | 27.2 | 119.2 | 140,398 | 27.6 | 112.0 | 158,034 | 31.6 | 112.6 | 174,000 | 32.5 |
中国 China | 93,373 | 25.7 | 111.4 | 96,902 | 23.6 | 103.8 | 109,952 | 23.9 | 113.5 | 117,970 | 23.2 | 107.3 | 89,465 | 17.9 | 75.8 | 75,000 | 14.0 |
ｱｼﾞｱ･ﾊﾟｼﾌｨｯｸ※1 Asia-Pacific | 36,780 | 28.0 | 127.6 | 42,661 | 28.9 | 116.0 | 45,241 | 9.8 | 106.0 | 51,339 | 10.1 | 113.5 | 54,649 | 10.9 | 106.4 | 62,000 | 11.6 |
海外 計 Overseas Total | 308,161 | 84.7 | 120.2 | 350,669 | 85.4 | 113.8 | 399,325 | 86.5 | 113.9 | 440,857 | 86.7 | 110.4 | 441,403 | 88.3 | 100.1 | 463,000 | 86.5 |
合 計 Total Sales | 363,780 | 100.0 | 119.2 | 410,502 | 100.0 | 112.8 | 461,510 | 100.0 | 112.4 | 508,643 | 100.0 | 110.2 | 500,006 | 100.0 | 98.3 | 535,000 | 100.0 |
EMEA︓欧州、中東、アフリカ地域 ●EMEA: Europe, the Middle East and Africa
※1 □シアの売上はEMEAからAPへ組み替えています。
※1 Sales for Russia have been recategorized from the EMEA segment to the AP segment.
事業別売上⾼ Net Sales by Business （百万円）（構成⽐・対前年⽐︓%）（JPY million）(Ratio･Y O Y︓%)
事業 Business
決算期 Fiscal Term
2022.3 FY
2023.3 FY
2024.3 FY
2025.3 FY
2026.3 FY
2027.3 通期予想
Forecast
Ratio
Y O Y
Ratio
Y O Y
Ratio
Y O Y
Ratio
Y O Y
Ratio
Y O Y
Ratio
⾎球計数検 査
Hematology
210,367
57.8
116.8
241,325
58.8
114.7
274,915
59.6
113.9
303,202
59.6
110.3
299,407
59.9
98.7
317,000
59.3
FCM検査
FCM
2,074
0.6
142.7
2,262
0.6
109.0
3,318
0.7
146.7
3,638
0.7
109.6
4,690
0.9
128.9
7,000
1.3
尿検査
Urinalysis
29,978
8.2
137.1
34,053
8.3
113.6
39,031
8.5
114.6
40,838
8.0
104.6
44,070
8.8
107.9
48,500
9.1
⾎液凝固検 査
Hemostasis
62,087
17.1
114.3
66,900
16.3
107.8
72,934
15.8
109.0
82,346
16.2
112.9
72,409
14.5
87.9
74,000
13.8
免疫検査
Immunochemistry
20,414
5.6
131.9
23,575
5.7
115.5
23,646
5.1
100.3
25,871
5.1
109.4
22,319
4.5
86.3
23,000
4.3
⽣化学検査
Clinical Chemistry
2,958
0.8
105.7
3,426
0.8
115.8
3,378
0.7
98.6
3,633
0.7
107.5
2,917
0.6
80.3
13,000
2.4
ライフサイエン ス
Life Science
17,980
4.9
138.1
19,937
4.9
110.9
20,508
4.4
102.9
21,324
4.2
104.0
24,960
5.0
117.1
23,500
4.4
その他
Others
16,624
4.6
108.6
16,686
4.1
100.4
20,030
4.3
120.0
22,417
4.4
111.9
25,925
5.2
115.7
23,500
4.4
ダイアグノスティ クス事業
Diagnostics Business
362,485
99.6
119.1
408,168
99.4
112.6
457,764
99.2
112.2
503,271
98.9
109.9
496,702
99.3
98.7
529,500
99.0
メディカル□ボット事業
合 計
Medical Robotics Business
Total Sales
1,294
363,780
0.4
100.0
167.1
119.2
2,333
410,502
0.6
100.0
180.2
112.8
3,745
461,510
0.8
100.0
160.5
112.4
5,371
508,643
1.1
100.0
143.4
110.2
3,304
500,006
0.7
100.0
61.5
98.3
5,500
535,000
1.0
100.0
品⽬別売上⾼ Net Sales by Product Type （百万円）（構成⽐・対前年⽐︓%）（JPY million）(Ratio･Y O Y︓%)
品⽬ Product
Type
決算期 Fiscal Term
2022.3 FY
2023.3 FY
2024.3 FY
2025.3 FY
2026.3 FY
2027.3 通期予想
Forecast
Ratio
Y O Y
Ratio
Y O Y
Ratio
Y O Y
Ratio
Y O Y
Ratio
Y O Y
Ratio
機器
Instrument
86,795
23.9
102.5
91,796
22.4
105.8
100,959
21.9
110.0
104,259
20.5
103.3
103,232
20.6
99.0
114,000
21.3
試薬
Reagent
216,167
59.4
126.9
247,535
60.3
114.5
280,843
60.9
113.5
313,818
61.7
111.7
307,923
61.6
98.1
322,000
60.2
サービス
Service
46,579
12.8
118.3
54,350
13.2
116.7
61,446
13.3
113.1
68,414
13.5
111.3
69,275
13.9
101.3
76,000
14.2
その他
合計
Others
Total Sales
14,238
363,780
3.9
100.0
132.8
119.2
16,819
410,502
4.1
100.0
118.1
112.8
18,261
461,510
4.0
100.0
108.6
112.4
22,150
508,643
4.4
100.0
121.3
110.2
19,575
500,006
3.9
100.0
88.4
98.3
23,000
535,000
4.3
100.0
●通期予想は、2026年5⽉に公表したものです 。
Business forecast was revised in May 2026.
地域別・事業別売上⾼ Net Sales by Destination and Business
決算期 Fiscal Term
2022.3 FY
2023.3 FY
2024.3 FY
2025.3 FY
2026.3 FY
⽇本 Japan （百万円）（構成⽐・対前年⽐︓%）（JPY million）(Ratio･Y O Y︓%)
事業 Business | Ratio | Y O Y | Ratio | Y O Y | Ratio | Y O Y | Ratio | Y O Y | Ratio | Y O Y | ||||||
⾎球計数検 査 | Hematology | 19,725 | 35.5 | 101.3 | 20,272 | 33.9 | 102.8 | 21,943 | 35.3 | 108.2 | 25,204 | 37.2 | 114.9 | 19,751 | 33.7 | 78.4 |
FCM検査 | FCM | 380 | 0.7 | 391.9 | 121 | 0.2 | 32.0 | 90 | 0.1 | 74.7 | 115 | 0.2 | 126.7 | 112 | 0.2 | 97.5 |
尿検査 | Urinalysis | 3,242 | 5.8 | 109.2 | 3,226 | 5.4 | 99.5 | 3,546 | 5.7 | 109.9 | 3,149 | 4.6 | 88.8 | 3,287 | 5.6 | 104.4 |
⾎液凝固検 査 | Hemostasis | 9,925 | 17.8 | 110.0 | 10,318 | 17.2 | 104.0 | 10,505 | 16.9 | 101.8 | 11,924 | 17.6 | 113.5 | 10,287 | 17.6 | 86.3 |
免疫検査 | Immunochemistry | 7,904 | 14.2 | 150.2 | 10,618 | 17.7 | 134.3 | 9,152 | 14.7 | 86.2 | 9,681 | 14.3 | 105.8 | 8,123 | 13.9 | 83.9 |
⽣化学検査 | Clinical Chemistry | 1,087 | 2.0 | 96.8 | 1,049 | 1.8 | 96.5 | 1,015 | 1.6 | 96.7 | 1,066 | 1.6 | 105.0 | 983 | 1.7 | 92.2 |
ライフサイエン ス | Life Science | 7,157 | 12.9 | 157.3 | 6,860 | 11.5 | 95.9 | 6,144 | 9.9 | 89.6 | 5,775 | 8.5 | 94.0 | 6,129 | 10.5 | 106.1 |
その他 | Others | 4,900 | 8.8 | 89.4 | 5,030 | 8.4 | 102.6 | 6,038 | 9.7 | 120.0 | 6,063 | 8.9 | 100.4 | 6,796 | 11.6 | 112.1 |
ダイアグノスティクス事業 | Diagnostics Business | 54,323 | 97.7 | 113.2 | 57,498 | 96.1 | 105.8 | 58,438 | 94.0 | 101.6 | 62,979 | 92.9 | 107.8 | 55,471 | 94.7 | 88.1 |
メディカル□ボット事業 | Medical Robotics Business | 1,294 | 2.3 | 167.1 | 2,333 | 3.9 | 180.2 | 3,745 | 6.0 | 160.5 | 4,807 | 7.1 | 128.3 | 3,132 | 5.3 | 65.2 |
合 計 | Total Sales | 55,618 | 100.0 | 114.1 | 59,832 | 100.0 | 107.6 | 62,184 | 100.0 | 103.9 | 67,786 | 100.0 | 109.0 | 58,603 | 100.0 | 86.5 |
海外 Overseas | ||||||||||||||||
決算期 Fiscal Term 2022.3 FY 2023.3 FY 2024.3 FY 2025.3 FY 2026.3 FY | ||||||||||||||||
事業 Business | Ratio | Y O Y | Ratio | Y O Y | Ratio | Y O Y | Ratio | Y O Y | Ratio | Y O Y | ||||||
⾎球計数検 査 | Hematology | 190,642 | 61.9 | 118.7 | 221,053 | 63.0 | 116.0 | 252,972 | 63.3 | 114.4 | 277,998 | 63.1 | 109.9 | 279,656 | 63.4 | 100.6 |
FCM検査 | FCM | 1,694 | 0.5 | 124.9 | 2,140 | 0.6 | 126.3 | 3,227 | 0.8 | 150.8 | 3,522 | 0.8 | 109.1 | 4,578 | 1.0 | 130.0 |
尿検査 | Urinalysis | 26,735 | 8.7 | 141.5 | 30,826 | 8.8 | 115.3 | 35,485 | 8.9 | 115.1 | 37,689 | 8.5 | 106.2 | 40,783 | 9.2 | 108.2 |
⾎液凝固検 査 | Hemostasis | 52,162 | 16.9 | 115.2 | 56,581 | 16.1 | 108.5 | 62,429 | 15.6 | 110.3 | 70,421 | 16.0 | 112.8 | 62,121 | 14.1 | 88.2 |
免疫検査 | Immunochemistry | 12,509 | 4.1 | 122.4 | 12,957 | 3.7 | 103.6 | 14,493 | 3.6 | 111.9 | 16,189 | 3.7 | 111.7 | 14,195 | 3.2 | 87.7 |
⽣化学検査 | Clinical Chemistry | 1,871 | 0.6 | 111.7 | 2,376 | 0.7 | 127.0 | 2,362 | 0.6 | 99.4 | 2,567 | 0.6 | 108.6 | 1,934 | 0.4 | 75.4 |
ライフサイエン ス | Life Science | 10,823 | 3.5 | 127.7 | 13,076 | 3.7 | 120.8 | 14,364 | 3.6 | 109.8 | 15,549 | 3.5 | 108.3 | 18,831 | 4.3 | 121.1 |
その他 | Others | 11,723 | 3.8 | 119.4 | 11,656 | 3.3 | 99.4 | 13,991 | 3.5 | 120.0 | 16,354 | 3.7 | 116.9 | 19,129 | 4.3 | 117.0 |
ダイアグノスティクス事業 | Diagnostics Business | 308,161 | 100.0 | 120.2 | 350,669 | 100.0 | 113.8 | 399,325 | 100.0 | 113.9 | 440,292 | 99.9 | 110.3 | 441,231 | 100.0 | 100.2 |
メディカル□ボット事業 | Medical Robotics Business | - | - | - | - | - | - | - | - | - | 564 | 0.1 | - | 172 | 0.0 | - |
合 計 | Total Sales | 308,161 | 100.0 | 120.2 | 350,669 | 100.0 | 113.8 | 399,325 | 100.0 | 113.9 | 440,857 | 100.0 | 110.4 | 441,403 | 100.0 | 100.1 |
9
決算期 Fiscal Term
2022.3 FY
2023.3 FY
2024.3 FY
2025.3 FY
2026.3 FY
⽶州 Americas （百万円）（構成⽐・対前年⽐︓%）（JPY million）(Ratio･Y O Y︓%)
事業 Business | Ratio | Y O Y | Ratio | Y O Y | Ratio | Y O Y | Ratio | Y O Y | Ratio | Y O Y | ||||||
⾎球計数検 査 | Hematology | 69,359 | 82.9 | 119.9 | 86,578 | 81.8 | 124.8 | 95,388 | 80.3 | 110.2 | 104,667 | 79.8 | 109.7 | 108,936 | 78.2 | 104.1 |
FCM検査 | FCM | 511 | 0.6 | 134.2 | 642 | 0.6 | 125.5 | 1,110 | 0.9 | 172.9 | 1,041 | 0.8 | 93.8 | 976 | 0.7 | 93.8 |
尿検査 | Urinalysis | 8,818 | 10.5 | 349.4 | 12,071 | 11.4 | 136.9 | 15,125 | 12.7 | 125.3 | 16,043 | 12.2 | 106.1 | 18,605 | 13.4 | 116.0 |
⾎液凝固検 査 | Hemostasis | 2,629 | 3.1 | 78.7 | 2,907 | 2.7 | 110.6 | 2,467 | 2.1 | 84.9 | 3,085 | 2.4 | 125.0 | 3,443 | 2.5 | 111.6 |
免疫検査 | Immunochemistry | 2 | 0.0 | 104.1 | 3 | 0.0 | 133.5 | 327 | 0.3 | 10,282.4 | 1,021 | 0.8 | 312.3 | 1,429 | 1.0 | 140.0 |
⽣化学検査 | Clinical Chemistry | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ライフサイエン ス | Life Science | 1,902 | 2.3 | 119.1 | 2,956 | 2.8 | 155.4 | 3,075 | 2.6 | 104.0 | 3,464 | 2.6 | 112.7 | 3,300 | 2.4 | 95.3 |
その他 | Others | 431 | 0.5 | 243.0 | 746 | 0.7 | 173.1 | 1,287 | 1.1 | 172.5 | 1,823 | 1.4 | 141.7 | 2,563 | 1.8 | 140.5 |
ダイアグノスティクス事業 | Diagnostics Business | 83,655 | 100.0 | 127.0 | 105,905 | 100.0 | 126.6 | 118,782 | 100.0 | 112.2 | 131,148 | 100.0 | 110.4 | 139,254 | 100.0 | 106.2 |
メディカル□ボット事業 | Medical Robotics Business | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
合 計 | Total Sales | 83,655 | 100.0 | 127.0 | 105,905 | 100.0 | 126.6 | 118,782 | 100.0 | 112.2 | 131,148 | 100.0 | 110.4 | 139,254 | 100.0 | 106.2 |
決算期 Fiscal Term
2022.3 FY
2023.3 FY
2024.3 FY
2025.3 FY
2026.3 FY
EMEA※1 （欧州、中東、アフリカ地域 / Europe, the Middle East and Africa）
事業 Business | Ratio | Y O Y | Ratio | Y O Y | Ratio | Y O Y | Ratio | Y O Y | Ratio | Y O Y | ||||||
⾎球計数検 査 | Hematology | 60,534 | 64.2 | 119.8 | 69,259 | 65.8 | 114.4 | 83,148 | 66.3 | 120.1 | 92,459 | 65.9 | 111.2 | 99,542 | 63.0 | 107.7 |
FCM検査 | FCM | 673 | 0.7 | 107.3 | 908 | 0.9 | 134.9 | 1,390 | 1.1 | 153.0 | 1,678 | 1.2 | 120.7 | 2,381 | 1.5 | 141.9 |
尿検査 | Urinalysis | 4,836 | 5.1 | 128.4 | 5,868 | 5.6 | 121.3 | 6,831 | 5.4 | 116.4 | 7,856 | 5.6 | 115.0 | 10,240 | 6.5 | 130.4 |
⾎液凝固検 査 | Hemostasis | 9,204 | 9.8 | 123.3 | 9,404 | 8.9 | 102.2 | 11,682 | 9.3 | 124.2 | 13,691 | 9.8 | 117.2 | 15,648 | 9.9 | 114.3 |
免疫検査 | Immunochemistry | 30 | 0.0 | 898.9 | 11 | 0.0 | 38.6 | 28 | 0.0 | 243.5 | 67 | 0.0 | 232.6 | 94 | 0.1 | 140.5 |
⽣化学検査 | Clinical Chemistry | 43 | 0.0 | 149.1 | 19 | 0.0 | 44.4 | 1 | 0.0 | 9.9 | 0 | 0.0 | 0.6 | 17 | 0.0 | - |
ライフサイエン ス | Life Science | 8,797 | 9.3 | 134.1 | 9,968 | 9.5 | 113.3 | 11,159 | 8.9 | 111.9 | 11,958 | 8.5 | 107.2 | 15,380 | 9.7 | 128.6 |
その他 | Others | 10,231 | 10.8 | 116.7 | 9,759 | 9.3 | 95.4 | 11,106 | 8.9 | 113.8 | 12,686 | 9.0 | 114.2 | 14,729 | 9.3 | 116.1 |
ダイアグノスティクス事業 | Diagnostics Business | 94,352 | 100.0 | 121.3 | 105,200 | 100.0 | 111.5 | 125,349 | 100.0 | 119.2 | 140,398 | 100.0 | 112.0 | 158,034 | 100.0 | 112.6 |
メディカル□ボット事業 | Medical Robotics Business | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
合 計 | Total Sales | 94,352 | 100.0 | 121.3 | 105,200 | 100.0 | 111.5 | 125,349 | 100.0 | 119.2 | 140,398 | 100.0 | 112.0 | 158,034 | 100.0 | 112.6 |
※1 □シアの売上はEMEAからAPへ組み替えています。
※1 Sales for Russia have been recategorized from the EMEA segment to the AP segment.
決算期 Fiscal Term
2022.3 FY
2023.3 FY
2024.3 FY
2025.3 FY
2026.3 FY
中国 China （百万円）（構成⽐・対前年⽐︓%）（JPY million）(Ratio･Y O Y︓%)
事業 Business | Ratio | Y O Y | Ratio | Y O Y | Ratio | Y O Y | Ratio | Y O Y | Ratio | Y O Y | ||||||
⾎球計数検 査 | Hematology | 37,465 | 40.1 | 113.2 | 36,804 | 38.0 | 98.2 | 44,362 | 40.3 | 120.5 | 46,850 | 39.7 | 105.6 | 34,602 | 38.7 | 73.9 |
FCM検査 | FCM | 184 | 0.2 | 112.2 | 294 | 0.3 | 159.3 | 123 | 0.1 | 41.9 | 118 | 0.1 | 95.9 | 329 | 0.4 | 278.5 |
尿検査 | Urinalysis | 10,115 | 10.8 | 96.9 | 9,220 | 9.5 | 91.2 | 9,771 | 8.9 | 106.0 | 9,649 | 8.2 | 98.8 | 7,429 | 8.3 | 77.0 |
⾎液凝固検 査 | Hemostasis | 33,177 | 35.5 | 112.4 | 37,688 | 38.9 | 113.6 | 42,264 | 38.4 | 112.1 | 47,100 | 39.9 | 111.4 | 35,985 | 40.2 | 76.4 |
免疫検査 | Immunochemistry | 11,531 | 12.3 | 120.6 | 11,725 | 12.1 | 101.7 | 12,326 | 11.2 | 105.1 | 13,088 | 11.1 | 106.2 | 10,392 | 11.6 | 79.4 |
⽣化学検査 | Clinical Chemistry | 845 | 0.9 | 105.1 | 1,099 | 1.1 | 130.0 | 1,000 | 0.9 | 91.1 | 1,068 | 0.9 | 106.8 | 641 | 0.7 | 60.1 |
ライフサイエン ス | Life Science | 53 | 0.1 | 21.3 | 53 | 0.1 | 99.9 | 76 | 0.1 | 144.9 | 59 | 0.1 | 77.2 | 67 | 0.1 | 113.7 |
その他 | Others | - | - | - | 16 | 0.0 | - | 25 | 0.0 | 156.4 | 35 | 0.0 | 135.7 | 16 | 0.0 | 45.8 |
ダイアグノスティクス事業 | Diagnostics Business | 93,373 | 100.0 | 111.4 | 96,902 | 100.0 | 103.8 | 109,952 | 100.0 | 113.5 | 117,970 | 100.0 | 107.3 | 89,465 | 100.0 | 75.8 |
メディカル□ボット事業 | Medical Robotics Business | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
合 計 | Total Sales | 93,373 | 100.0 | 111.4 | 96,902 | 100.0 | 103.8 | 109,952 | 100.0 | 113.5 | 117,970 | 100.0 | 107.3 | 89,465 | 100.0 | 75.8 |
決算期 Fiscal Term
2022.3 FY
2023.3 FY
2024.3 FY
2025.3 FY
2026.3 FY
アジア・パシ フィック※1
Asia-Pacific
事業 Business | Ratio | Y O Y | Ratio | Y O Y | Ratio | Y O Y | Ratio | Y O Y | Ratio | Y O Y | ||||||
⾎球計数検 査 | Hematology | 23,283 | 63.3 | 122.1 | 28,410 | 66.6 | 122.0 | 30,071 | 66.5 | 105.8 | 34,021 | 66.3 | 113.1 | 36,574 | 66.9 | 107.5 |
FCM検査 | FCM | 323 | 0.9 | 177.7 | 294 | 0.7 | 91.1 | 602 | 1.3 | 204.4 | 684 | 1.3 | 113.6 | 891 | 1.6 | 130.2 |
尿検査 | Urinalysis | 2,965 | 8.1 | 136.7 | 3,666 | 8.6 | 123.6 | 3,756 | 8.3 | 102.5 | 4,139 | 8.1 | 110.2 | 4,507 | 8.2 | 108.9 |
⾎液凝固検 査 | Hemostasis | 7,150 | 19.4 | 143.8 | 6,582 | 15.4 | 92.0 | 6,014 | 13.3 | 91.4 | 6,543 | 12.7 | 108.8 | 7,044 | 12.9 | 107.7 |
免疫検査 | Immunochemistry | 944 | 2.6 | 144.5 | 1,216 | 2.9 | 128.7 | 1,810 | 4.0 | 148.8 | 2,013 | 3.9 | 111.2 | 2,279 | 4.2 | 113.2 |
⽣化学検査 | Clinical Chemistry | 982 | 2.7 | 116.7 | 1,258 | 2.9 | 128.1 | 1,360 | 3.0 | 108.1 | 1,498 | 2.9 | 110.2 | 1,275 | 2.3 | 85.1 |
ライフサイエン ス | Life Science | 69 | 0.2 | 109.6 | 98 | 0.2 | 140.8 | 52 | 0.1 | 53.2 | 66 | 0.1 | 126.9 | 83 | 0.2 | 125.7 |
その他 | Others | 1,061 | 2.9 | 120.7 | 1,134 | 2.7 | 106.9 | 1,572 | 3.5 | 138.6 | 1,808 | 3.5 | 115.0 | 1,820 | 3.3 | 100.7 |
ダイアグノスティクス事業 | Diagnostics Business | 36,780 | 100.0 | 127.6 | 42,661 | 100.0 | 116.0 | 45,241 | 100.0 | 106.0 | 50,775 | 98.9 | 112.2 | 54,477 | 99.7 | 107.3 |
メディカル□ボット事業 | Medical Robotics Business | - | - | - | - | - | - | - | - | - | 564 | 1.1 | - | 172 | 0.3 | 30.5 |
合 計 | Total Sales | 36,780 | 100.0 | 127.6 | 42,661 | 100.0 | 116.0 | 45,241 | 100.0 | 106.0 | 51,339 | 100.0 | 113.5 | 54,649 | 100.0 | 106.4 |
※1 □シアの売上はEMEAからAPへ組み替えています。
※1 Sales for Russia have been recategorized from the EMEA segment to the AP segment.
11
地域別・品⽬別売上⾼ Net Sales by Destination and Product type （百万円）（構成⽐・対前 年⽐︓%）（JPY million）(Ratio･Y O Y︓%)
決算期 Fiscal Term 地域 Destination/品⽬ Product Type | 2022.3 FY | 2023.3 FY | 2024.3 FY | 2025.3 FY | 2026.3 FY | ||||||||||||
Ratio | Y O Y | Ratio | Y O Y | Ratio | Y O Y | Ratio | Y O Y | Ratio | Y O Y | ||||||||
機器 | Instrument | 10,647 | 19.1 | 102.1 | 11,538 | 19.3 | 108.4 | 14,713 | 23.7 | 127.5 | 16,229 | 23.9 | 110.3 | 11,002 | 18.8 | 67.8 | |
試薬 | Reagent | 35,521 | 63.9 | 120.3 | 38,003 | 63.5 | 107.0 | 36,631 | 58.9 | 96.4 | 39,142 | 57.7 | 106.9 | 34,403 | 58.7 | 87.9 | |
⽇本 | サービス | Service | 7,400 | 13.3 | 103.5 | 8,024 | 13.4 | 108.4 | 8,310 | 13.4 | 103.6 | 8,796 | 13.0 | 105.9 | 10,015 | 17.1 | 113.9 |
Japan | その他 | Others | 2,048 | 3.7 | 124.4 | 2,265 | 3.8 | 110.6 | 2,529 | 4.1 | 111.7 | 3,618 | 5.3 | 143.0 | 3,181 | 5.4 | 87.9 |
合計 | Total Sales | 55,618 | 100.0 | 114.1 | 59,832 | 100.0 | 107.6 | 62,184 | 100.0 | 103.9 | 67,786 | 100.0 | 109.0 | 58,603 | 100.0 | 86.5 | |
機器 | Instrument | 23,044 | 27.5 | 124.5 | 28,927 | 27.3 | 125.5 | 31,068 | 26.2 | 107.4 | 29,007 | 22.1 | 93.4 | 32,846 | 23.6 | 113.2 | |
試薬 | Reagent | 38,550 | 46.1 | 130.4 | 49,103 | 46.4 | 127.4 | 56,804 | 47.8 | 115.7 | 66,076 | 50.4 | 116.3 | 68,417 | 49.1 | 103.5 | |
⽶州 | サービス | Service | 21,055 | 25.2 | 123.7 | 26,161 | 24.7 | 124.3 | 29,076 | 24.5 | 111.1 | 33,102 | 25.2 | 113.8 | 35,034 | 25.2 | 105.8 |
Americas | その他 | Others | 1,005 | 1.2 | 126.6 | 1,713 | 1.6 | 170.4 | 1,834 | 1.5 | 107.1 | 2,962 | 2.3 | 161.5 | 2,955 | 2.1 | 99.8 |
合計 | Total Sales | 83,655 | 100.0 | 127.0 | 105,905 | 100.0 | 126.6 | 118,782 | 100.0 | 112.2 | 131,148 | 100.0 | 110.4 | 139,254 | 100.0 | 106.2 | |
機器 | Instrument | 24,439 | 25.9 | 112.7 | 27,288 | 25.9 | 111.7 | 30,468 | 24.3 | 111.7 | 32,655 | 23.3 | 107.2 | 37,672 | 23.8 | 115.4 | |
※1 | 試薬 | Reagent | 53,843 | 57.1 | 125.1 | 60,851 | 57.8 | 113.0 | 75,255 | 60.0 | 123.7 | 86,128 | 61.3 | 114.4 | 96,446 | 61.0 | 112.0 |
EMEA | サービス | Service | 10,552 | 11.2 | 116.1 | 11,292 | 10.7 | 107.0 | 13,326 | 10.6 | 118.0 | 15,036 | 10.7 | 112.8 | 16,207 | 10.3 | 107.8 |
その他 | Others | 5,516 | 5.8 | 139.4 | 5,768 | 5.5 | 104.6 | 6,299 | 5.0 | 109.2 | 6,577 | 4.7 | 104.4 | 7,706 | 4.9 | 117.2 | |
合計 | Total Sales | 94,352 | 100.0 | 121.3 | 105,200 | 100.0 | 111.5 | 125,349 | 100.0 | 119.2 | 140,398 | 100.0 | 112.0 | 158,034 | 100.0 | 112.6 | |
機器 | Instrument | 20,201 | 21.6 | 76.4 | 15,153 | 15.6 | 75.0 | 15,030 | 13.7 | 99.2 | 15,512 | 13.1 | 103.2 | 11,503 | 12.9 | 74.2 | |
試薬 | Reagent | 63,036 | 67.5 | 127.8 | 69,469 | 71.7 | 110.2 | 81,791 | 74.4 | 117.7 | 87,355 | 74.0 | 106.8 | 68,645 | 76.7 | 78.6 | |
中国 | サービス | Service | 5,756 | 6.2 | 123.7 | 6,687 | 6.9 | 116.2 | 7,318 | 6.7 | 109.4 | 7,924 | 6.7 | 108.3 | 5,553 | 6.2 | 70.1 |
China | その他 | Others | 4,379 | 4.7 | 129.2 | 5,592 | 5.8 | 127.7 | 5,813 | 5.3 | 104.0 | 7,178 | 6.1 | 123.5 | 3,763 | 4.2 | 52.4 |
合計 | Total Sales | 93,373 | 100.0 | 111.4 | 96,902 | 100.0 | 103.8 | 109,952 | 100.0 | 113.5 | 117,970 | 100.0 | 107.3 | 89,465 | 100.0 | 75.8 | |
ｱｼﾞｱ･※1 ﾊﾟｼﾌｨｯｸ Asia- Pacific | 機器 | Instrument | 8,462 | 23.0 | 111.3 | 8,889 | 20.8 | 105.0 | 9,679 | 21.4 | 108.9 | 10,854 | 21.1 | 112.1 | 10,206 | 18.7 | 94.0 |
試薬 | Reagent | 25,216 | 68.6 | 133.9 | 30,107 | 70.6 | 119.4 | 30,360 | 67.1 | 100.8 | 35,115 | 68.4 | 115.7 | 40,010 | 73.2 | 113.9 | |
サービス | Service | 1,813 | 4.9 | 124.5 | 2,185 | 5.1 | 120.5 | 3,415 | 7.6 | 156.3 | 3,555 | 6.9 | 104.1 | 2,463 | 4.5 | 69.3 | |
その他 | Others | 1,287 | 3.5 | 138.3 | 1,479 | 3.5 | 114.9 | 1,785 | 3.9 | 120.7 | 1,814 | 3.5 | 101.6 | 1,968 | 3.6 | 108.5 | |
合計 | Total Sales | 36,780 | 100.0 | 127.6 | 42,661 | 100.0 | 116.0 | 45,241 | 100.0 | 106.0 | 51,339 | 100.0 | 113.5 | 54,649 | 100.0 | 106.4 | |
機器 | Instrument | 86,795 | 23.9 | 102.5 | 91,796 | 22.4 | 105.8 | 100,959 | 21.9 | 110.0 | 104,259 | 20.5 | 103.3 | 103,232 | 20.6 | 99.0 | |
試薬 | Reagent | 216,167 | 59.4 | 126.9 | 247,535 | 60.3 | 114.5 | 280,843 | 60.9 | 113.5 | 313,818 | 61.7 | 111.7 | 307,923 | 61.6 | 98.1 | |
計 | サービス | Service | 46,579 | 12.8 | 118.3 | 54,350 | 13.2 | 116.7 | 61,446 | 13.3 | 113.1 | 68,414 | 13.5 | 111.3 | 69,275 | 13.9 | 101.3 |
Total | その他 | Others | 14,238 | 3.9 | 132.8 | 16,819 | 4.1 | 118.1 | 18,261 | 4.0 | 108.6 | 22,150 | 4.4 | 121.3 | 19,575 | 3.9 | 88.4 |
合計 | Total Sales | 363,780 | 100.0 | 119.2 | 410,502 | 100.0 | 112.8 | 461,510 | 100.0 | 112.4 | 508,643 | 100.0 | 110.2 | 500,006 | 100.0 | 98.3 | |
EMEA︓欧州、中東、アフリカ地域 ●EMEA: Europe, the Middle East and Africa
※1 □シアの売上はEMEAからAPへ組み替えています。
※1 Sales for Russia have been recategorized from the EMEA segment to the AP segment.
（百万円）（構成⽐・対前年⽐︓%）（JPY million）(Ratio･Y O Y︓%)
統括会社 Managing
company
決算期 Fiscal Term
2022.3 FY
2023.3 FY
2024.3 FY
2025.3 FY
2026.3 FY
Ratio
Y O Y
Ratio
Y O Y
Ratio
Y O Y
Ratio
Y O Y
Ratio
Y O Y
本社統括
Headquarters
外部売 上⾼
Sales to Customers
73,607
37.0
113.2
78,832
35.9
107.1
85,642
35.9
108.6
93,988
36.8
109.7
87,562
40.2
93.2
内部売 上⾼
Intra-area Transfer
125,515
63.0
118.8
141,062
64.1
112.4
152,958
64.1
108.4
161,269
63.2
105.4
130,449
59.8
80.9
売上⾼ 計
Total Sales
199,123
100.0
116.7
219,894
100.0
110.4
238,601
100.0
108.5
255,258
100.0
107.0
218,011
100.0
85.4
営業利益
Operating Income
38,729
19.4
134.2
48,484
22.0
125.2
54,309
22.8
112.0
59,104
23.2
108.8
17,771
8.2
30.1
⽶州統括
Americas RHQ
外部売 上⾼
Sales to Customers
78,501
100.0
128.4
100,428
100.0
127.9
111,997
100.0
111.5
122,916
100.0
109.7
130,456
100.0
106.1
内部売 上⾼
Intra-area Transfer
22
0.0
225.0
46
0.0
206.3
35
0.0
77.1
30
0.0
84.2
25
0.0
85.8
売上⾼ 計
Total Sales
78,524
100.0
128.4
100,475
100.0
128.0
112,033
100.0
111.5
122,946
100.0
109.7
130,482
100.0
106.1
営業利益
Operating Income
5,447
6.9
168.1
5,488
5.5
100.8
7,399
6.6
134.8
6,743
5.5
91.1
8,507
6.5
126.1
※1
EMEA統括 EMEA RHQ
外部売 上⾼
Sales to Customers
91,135
94.2
121.6
102,801
96.3
112.8
121,568
99.2
118.3
135,671
99.6
111.6
152,110
99.5
112.1
内部売 上⾼
Intra-area Transfer
5,568
5.8
131.2
3,942
3.7
70.8
992
0.8
25.2
604
0.4
61.0
786
0.5
130.0
売上⾼ 計
Total Sales
96,703
100.0
122.1
106,744
100.0
110.4
122,560
100.0
114.8
136,276
100.0
111.2
152,896
100.0
112.2
営業利益
Operating Income
11,079
11.5
118.9
11,225
10.5
101.3
10,327
8.4
92.0
10,583
7.8
102.5
9,904
6.5
93.6
中国統括
China RHQ
外部売 上⾼
Sales to Customers
93,295
99.9
111.4
96,797
100.0
103.8
109,797
99.6
113.4
117,828
99.6
107.3
89,296
99.6
75.8
内部売 上⾼
Intra-area Transfer
56
0.1
7,025.8
45
0.0
81.3
478
0.4
1,042.4
489
0.4
102.3
323
0.4
66.2
売上⾼ 計
Total Sales
93,351
100.0
111.5
96,843
100.0
103.7
110,276
100.0
113.9
118,317
100.0
107.3
89,619
100.0
75.7
営業利益
Operating Income
11,572
12.4
228.4
9,968
10.3
86.1
7,852
7.1
78.8
10,646
9.0
135.6
9,343
10.4
87.8
※1
AP統括
AP RHQ
外部売 上⾼
Sales to Customers
27,240
99.9
134.5
31,641
99.8
116.2
32,503
99.8
102.7
38,239
99.9
117.6
40,581
99.9
106.1
内部売 上⾼
Intra-area Transfer
29
0.1
76.2
64
0.2
217.9
52
0.2
81.0
50
0.1
96.6
50
0.1
99.7
売上⾼ 計
Total Sales
27,270
100.0
134.4
31,706
100.0
116.3
32,555
100.0
102.7
38,289
100.0
117.6
40,631
100.0
106.1
営業利益
Operating Income
2,228
8.2
116.7
1,983
6.3
89.0
2,376
7.3
119.8
3,579
9.3
150.7
3,707
9.1
103.6
計
Total
外部売 上⾼
Sales to Customers
363,780
73.5
119.2
410,502
73.9
112.8
461,510
74.9
112.4
508,643
75.8
110.2
500,006
79.2
98.3
内部売 上⾼
Intra-area Transfer
131,192
26.5
119.3
145,161
26.1
110.6
154,517
25.1
106.4
162,444
24.2
105.1
131,635
20.8
81.0
売上⾼ 計
Total Sales
494,972
100.0
119.3
555,663
100.0
112.3
616,027
100.0
110.9
671,088
100.0
108.9
631,641
100.0
94.1
営業利益
Operating Income
69,056
14.0
142.7
77,151
13.9
111.7
82,265
13.4
106.6
90,657
13.5
110.2
49,232
7.8
54.3
消去/全社
Eliminations/
Corporate
外部売 上⾼
Sales to Customers
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
内部売 上⾼
Intra-area Transfer
△131,192
-
-
△145,161
-
-
△154,517
-
-
△162,444
-
-
△131,635
-
-
売上⾼ 計
Total Sales
△131,192
-
-
△145,161
-
-
△154,517
-
-
△162,444
-
-
△131,635
-
-
営業利益
Operating Income
△1,640
-
-
△3,471
-
-
△3,882
-
-
△3,073
-
-
2,598
-
-
連結
Consolidated
外部売 上⾼
Sales to Customers
363,780
100.0
119.2
410,502
100.0
112.8
461,510
100.0
112.4
508,643
100.0
110.2
500,006
100.0
98.3
内部売 上⾼
Intra-area Transfer
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
売上⾼ 計
Total Sales
363,780
100.0
119.2
410,502
100.0
112.8
461,510
100.0
112.4
508,643
100.0
110.2
500,006
100.0
98.3
営業利益
Operating Income
67,416
18.5
134.8
73,679
17.9
109.3
78,382
17.0
106.4
87,583
17.2
111.7
51,831
10.4
59.2
EMEA︓欧州、中東、アフリカ地域 ●EMEA: Europe, the Middle East and Africa
※1 □シアの売上、利益はEMEA統括からAP統括へ組み替えています。
※1 Sales and profits for Russia have been recategorized from the EMEA segment to the AP segment.
13
関連データ Associated Data
株式情報 Stock Information
株価推移 Stock Price Range of Sysmex Corporation 株式の所有者別状況 Composition of Shareholders by Category
※1
(円) (JPY) 18,000
16,000
14,000
12,000
10,000
8,000
6,000
4,000
2,000
0
'16/3 '16/9 '17/3 '17/9 '18/3 '18/9 '19/3 '19/9 '20/3 '20/9 '21/3 '21/9 '22/3 '22/9 '23/3 '23/9 '24/3 '24/9 '25/3 '25/9 '26/3
※1. 2024年4⽉1⽇付︓株式分割（1:3） ※ Three-for-one stock split conducted on April 1, 2024
⾦融機関
Financial Institutions
⾦融商品取引 業者
Financial Instruments Firm
その他国 内法⼈ Other Japanese Companies
外国法⼈等
Foreign Investors
個⼈、その他
Individuals and Others
（） 株式数
Number of shares
<>保有者数
Number of shereholders
18.29%
(115,141,012)
<51,306>
36.40%
(229,115,838)
<958>
20.95%
(131,854,122)
<40>
2.43%
(15,307,135)
<51>
21.93%
(138,061,969)
<412>
(2026年3⽉31⽇ 現在) (As of March 31, 2026)
出来⾼ Trading Volume of Sysmex Corporation 株主数の推移 発⾏済株式数 の推移
(万株) (10 thousand shares)
Number of Shareholders
(名)
Number of Shares Issued
(千株)
9000
8000
7000
6000
5000
(Shareholders)
52,767
(thousand shares)
629,473 629,480
※1
19,916
20,553
16,847
14,643
629,371
※1
629,079
628,971
4000
3000
2000
1000
0
'16/3 '16/9 '17/3 '17/9 '18/3 '18/9 '19/3 '19/9 '20/3 '20/9 '21/3 '21/9 '22/3 '22/9 '23/3 '23/9 '24/3 '24/9 '25/3 '25/9 '26/3
'22.3 '23.3 '24.3 '25.3 '26.03
'22.3 '23.3 '24.3 '25.3 '26.03
※1. 2024年4⽉1⽇付︓株式分割（1:3）
シスメックス株式会社
Sysmex Corporation
本社所在地 〒651-0073 兵庫県神⼾市中央区脇浜海岸通1丁⽬5番1号
Address of Head Office 1-5-1, Wakinohama-Kaigandori, Chuo-ku,Kobe, Hyogo 651-0073, Japan
電話番号／Telephone (078)265-0500（代表）
FAX／Facsimile (078)265-0524
設⽴年⽉⽇／Date of Establishment 1968年2⽉20⽇／February 20,1968
資本⾦（千円）／Paid-in Capital (JPY thousand) 14,898,512
従業員数 ※嘱託及びパートタイマーなどを含む／Number of Employees ※Including part-time employee
単独（名）／Non-Consolidated 3,502
連結（名）／Consolidated 11,731
従業員平均年齢（才）／average age 42.4
従業員平均勤続年数（年）／average years of employment 12.8
発⾏済株式総数（千株）／Number of Shares Issued(thousand shares) 629,480
決算期／Settlement Day 3⽉31⽇／March 31
上場市場／Stock Listings 東京証券取引所 プライム市場／Tokyo Stock Exchange, Prime Market
証券コード／Stock Exchange Code Number 6869
主な事業内容 臨床検査機器、検査⽤試薬ならびに関連ソフトウェアなどの開発・製造 ・販売・輸出⼊
Main Line of Business Development,manufacture, sales, import and export of diagnostics testing instruments and reagents, and related software
主な販売先 国⽴病院、⼀般病院、⼤学、研究所、その他医療機関
Customers National and public hospitals, general hospitals, and other medical institutions, universities, and research institutes
(2026年3⽉31⽇現在) (As of March 31, 2026)
15
1-5-1 Wakinohama-Kaigandori, Chuo-ku, Kobe 651-0073, Japan
Tel. +81 (78) 265-0500 Fax. +81 (78) 265-0524
Printed in Japan